Blossomhill Therapeutics今日宣布，美国食品药品监督管理局（FDA）已授予其候选药物Bh-30643快速通道资格。该药物是一种宏环Omni-Egfr™抑制剂，专为治疗携带EGFR C797S突变的晚期非小细胞肺癌（NSCLC）患者而设计。
这一资格认定意味着Bh-30643有望加速开发和审评进程，以应对当前未被满足的医疗需求。EGFR C797S突变常被视为对现有靶向治疗产生耐药性的关键机制之一，临床挑战严峻。
Blossomhill Therapeutics表示，获得快速通道资格是其推进创新疗法过程中的重要里程碑。公司正全力推进该药物的临床开发，期待为患者带来新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.